Eli Lilly and Company has announced an additional $4.5-billion investment across two of its three sites in Lebanon, Indiana, which brings the company’s total Indiana capital expansion commitments since 2020 to more than $21 billion.  

The investment will incorporate new process designs and technologies at Lilly Lebanon API, one of the company’s future active pharmaceutical ingredient (API) sites, as well as Lilly Lebanon Advanced Therapies, the company’s first dedicated genetic medicine manufacturing facility that will support clinical and commercial production. This facility is the first of three planned sites on the Lebanon campus, which will also include Lilly Lebanon API and the Lilly Medicine Foundry, a new center for advanced manufacturing to support production of various molecular therapies, including drug substances for small molecules, biologics and nucleic acid therapies. New technologies developed at the Medicine Foundry will be transferred to Lilly’s other manufacturing sites for full-scale production. 

Lebanon, Indiana, is the cornerstone of Lilly’s domestic manufacturing buildout. In 2024, Lilly announced plans to make its blockbuster drugs, Mounjaro/Zepbound (tirzepatide), respectively approved for Type 2 diabetes and obesity/weight management, at its Lebanon API site. The new $4.5-billion investment expands that commitment further, including planned production of Foundayo (orforglipron), the company’s once-daily pill for weight loss, which received FDA approval last month (April 2026), and retatrutide, an investigational triple hormone receptor agonist in late-stage development for obesity and cardiometabolic disease. Analysts project blockbuster status for both drugs.   

Lilly says its US  capital expansion commitments have totaled more than $50 billion since 2020. Other US investments announced by the company since  February 2025 include the following: 

• Virginia: $5 billion for a new API and drug-product manufacturing facility, including for the company’s emerging bioconjugate platform and monoclonal antibody portfolio;    

• Texas: $6.5 billion for a new small-molecule API manufacturing facility;   

• Puerto Rico: $1.2 billion to expand an existing facility for oral solid medicines, including for manufacturing orforglipron. 

• Pennsylvania: $3.5 billion for an injectable medicine and device manufacturing facility that will produce weight-loss therapies. 

Source: Eli Lilly and Company